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Abstract
Aims
To analyse the treatment and control of dyslipidaemia in patients at high and very high car-
diovascular risk being treated for the primary prevention of cardiovascular disease (CVD) in
Europe.
Methods and Results
Data were assessed from the European Study on Cardiovascular Risk Prevention and Man-
agement in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336),
which included a randomly sampled population of primary CVD prevention patients from 12
European countries (n = 7641). Patients’ 10-year risk of CVD-related mortality was calculat-
ed using the Systematic Coronary Risk Evaluation (SCORE) algorithm, identifying 5019
patients at high cardiovascular risk (SCORE5% and/or receiving lipid-lowering therapy),
and 2970 patients at very high cardiovascular risk (SCORE10% or with diabetes
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mellitus). Among high-risk individuals, 65.3% were receiving lipid-lowering therapy, and
61.3% of treated patients had uncontrolled low-density lipoprotein cholesterol (LDL-C)
levels (2.5 mmol/L). For very-high-risk patients (uncontrolled LDL-C levels defined as
1.8 mmol/L) these figures were 49.5% and 82.9%, respectively. Excess 10-year risk of
CVD-related mortality (according to SCORE) attributable to lack of control of dyslipidaemia
was estimated to be 0.72% and 1.61% among high-risk and very-high-risk patients, respec-
tively. Among high-risk individuals with uncontrolled LDL-C levels, only 8.7% were receiving
a high-intensity statin (atorvastatin40 mg/day or rosuvastatin20 mg/day). Among very-
high-risk patients, this figure was 8.4%.
Conclusions
There is a considerable opportunity for improvement in rates of lipid-lowering therapy use
and achievement of lipid-level targets in high-risk and very-high-risk patients being treated
for primary CVD prevention in Europe.
Introduction
Elevated serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels are
among the primary causal risk factors for cardiovascular disease (CVD) [1, 2, 3]. We have pre-
viously shown in the European Study on Cardiovascular Risk Prevention and Management in
Usual Daily Practice (EURIKA; ClinicalTrials.gov identifier: NCT00882336) that dyslipidae-
mia remains prevalent in Europe, with a total of 57.7% of patients with at least one major risk
factor for CVD but no history of cardiovascular events (a primary CVD prevention popula-
tion) being dyslipidaemic [4]. Among the general population in Europe, prevalence estimates
for dyslipidaemia range between approximately 30% and 60% [5, 6, 7, 8, 9, 10].
The European guidelines on CVD prevention recommend adapting strategies for the prima-
ry prevention of CVD in accordance with patients’ overall level of cardiovascular risk [3].
According to these guidelines, global cardiovascular risk in individual patients should be as-
sessed using the Systematic Coronary Risk Evaluation (SCORE) algorithm, which estimates pa-
tients’ 10-year risk of death due to CVD based on their age, sex, smoking status, blood
pressure, and lipid levels [1, 3, 11, 12]. Patients are considered to be at high cardiovascular risk
if they have a SCORE of5 to<10%, type 1 or 2 diabetes mellitus with no other cardiovascular
risk factors, or moderate chronic kidney disease. Patients are considered to be at very-high-risk
if they have a SCORE of10%, a history of CVD, type 1 or 2 diabetes mellitus with other car-
diovascular risk factors or target organ damage, or severe chronic kidney disease [3].
Recommended target levels for total cholesterol are<5 mmol/L for all individuals, and rec-
ommended target levels for LDL-C are<3 mmol/L for those at intermediate cardiovascular
risk,<2.5 mmol/L for those at high-risk and<1.8 mmol/L or at least a 50% reduction for those
at very-high-risk. For individuals exceeding these recommended levels, lifestyle advice is rec-
ommended for those at intermediate-risk, with drug treatment to be considered if levels remain
uncontrolled, and by early drug intervention for those at high-risk or very-high-risk [3]. Statins
are recommended as the therapy of first choice in patients requiring pharmacological interven-
tion to reduce total cholesterol and LDL-C levels [3]. Most guidelines suggest that statin thera-
py should be considered to reduce global CVD risk in patients at high-risk and very-high-risk
even if total cholesterol and LDL-C concentrations are at or below target levels [12, 13]. The
Use of Lipid Lowering Therapy and LDL-C Goal Achievement in Europe
PLOS ONE | DOI:10.1371/journal.pone.0115270 February 18, 2015 2 / 11
contents of the manuscript and the decision to submit
it for publication. Writing support was provided by Ox-
ford PharmaGenesis Ltd, Oxford, UK, and was
funded by AstraZeneca.
Competing Interests: The authors have the follow-
ing interests. Julian P. Halcox and Jean Dallongeville
have received speaker and consulting fees from
AstraZeneca. Florence Tubach and Eliseo Guallar
have received research funding from AstraZeneca.
Stephen Sweet is an employee of Oxford Pharma-
Genesis Ltd, which has received funding from Astra-
Zeneca. Jesús Medina and Ogün Sazova are
employees of AstraZeneca. The EURIKA study was
funded by a commercial source (AstraZeneca). Writ-
ing support was provided by Oxford PharmaGenesis
Ltd, Oxford, UK, and was funded by AstraZeneca.
The rest of the authors declare that they have no
competing interests. There are no patents, products
in development or marketed products to declare. This
does not alter the authors0 adherence to all the PLOS
ONE policies on sharing data and materials, as de-
tailed online in the guide for authors.
recent ACC and AHA guidelines in the USA no longer recommend a target based approach to
the use of lipid lowering therapy. High or moderate intensity statin therapy is recommended
according to the risk status of the individual patient. In contrast, the European guidelines con-
tinue to recommend a target-based approach [14, 15].
As a further analysis of the data from EURIKA, we have assessed how dyslipidaemia is treat-
ed throughout Europe, specifically exploring how well patients’ cholesterol levels are controlled
and what potential evidence-based improvements in therapy could be considered for those not
at guideline-recommended target cholesterol levels.
Methods
Study design and participants
EURIKA was carried out in 12 European countries (Austria, Belgium, France, Germany,
Greece, Norway, Russia, Spain, Sweden, Switzerland, Turkey, and the UK) [4]. Data collection
started in May 2009 and ended in January 2010, with a 3-month data collection period for each
country. The study protocol was approved by the appropriate clinical research ethics commit-
tees in each participating country, and all patients provided signed informed consent.
The methods for the study have been reported in detail elsewhere [16]. Briefly, the study
sample was selected in a two-stage process that involved the random selection of both physi-
cians and their patients [16, 17]. In the first stage, primary care practitioners (PCPs) and spe-
cialists involved in CVD prevention (including cardiologists, endocrinologists, and internal
medicine specialists) were randomly selected for invitation to participate using the OneKey
database (Cegedim Dendrite, Boulogne-Billancourt, France) [18]. In total, 809 physicians
(approximately 60 per country) agreed to participate in EURIKA, 64% of whom were PCPs
[17]. Other physician specialties included cardiology, internal medicine and endocrinology. In
the second stage, participating physicians invited patients who met the selection criteria
(age 50 years or older, free of CVD but having at least one major cardiovascular risk factor
[dyslipidaemia, hypertension, smoking, diabetes mellitus, or obesity]) [4]. Approximately 600
patients were included in the EURIKA population per country, with a final population size of
7641. For the present analysis, included patients were those at high CVD risk, defined as those
with a SCORE of5% and/or who were already receiving lipid-lowering therapy, or very-high
CVD risk, defined as those who had a SCORE of10% or diabetes mellitus. The majority of
the very-high-risk patients were also analysed as part of the high-risk group.
Assessment of CVD risk factors
Demographic information and other details of participating patients were gathered from medi-
cal records and patient interviews. For each patient, a physical exam was conducted, blood
pressure was measured, and a 12-hour fasting blood sample was collected within 1 day of the
initial outpatient consultation [16]. Blood pressure measurements were obtained under stan-
dardized conditions for each patient, and blood sample analysis was carried out at a central lab-
oratory (BioAnalytical Research Corporation, Ghent, Belgium) with the exception of patients
in Russia, for whom laboratory analysis was carried out locally. High-density lipoprotein cho-
lesterol (HDL-C) concentration was measured by a modified enzymatic method, total choles-
terol concentration by the CHOD-PAP method, and triglyceride concentration by the GPO-
PAP method (all using the Roche Modular P chemistry analyser [Roche Diagnostics, IN,
USA]). LDL-C concentration was calculated by the Friedewald formula [19]. Ten-year CVD-
related mortality risk for each patient was estimated using the SCORE algorithms for high-risk
and low-risk countries, as appropriate [1].
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Lipid-lowering therapy and control of dyslipidaemia
The use of lipid-lowering therapy, including agents and dosing regimens used, was determined
for all patients. For statin treatment, therapy was categorized as low-intensity (pravastatin, sim-
vastatin, lovastatin, fluvastatin, atorvastatin<40 mg/day, or rosuvastatin<20 mg/day) or
high-intensity (atorvastatin40 mg/day or rosuvastatin20 mg/day). Control of dyslipidae-
mia was defined as LDL-C levels<2.5 mmol/L in high-risk patients and<1.8 mmol/L in very-
high-risk patients (when very-high-risk patients were analysed as part of the high-risk group,
the former definition was used).
CVD-related mortality risk attributable to lack of control of dyslipidaemia
The excess CVD-related mortality risk (attributable risk; AR) and the percentage of CVD-
related mortality risk (%AR) that is attributable to the lack of control of dyslipidaemia was
calculated among both high-risk and very-high-risk patients. AR was defined as the absolute
difference in SCORE-based, CVD-related mortality risk between the total EURIKA population
and these high-risk and very-high-risk participants if all of them had controlled dyslipidaemia
(i.e. the complementary risks thus calculated would represent the potential improvement in
CVD-related mortality that could be obtained by improving control of dyslipidaemia in these
individuals). The %AR was calculated as AR divided by the CVD-related mortality risk in the
total EURIKA population; it represents the percentage of CVD-related mortality among the
total EURIKA population that is due to the lack of dyslipidaemia control in high-risk and very-
high-risk patients for whom medical therapy is recommended (thus, it estimates the potential
improvement in CVD-related mortality among the EURIKA population that might be
achieved by effective control of dyslipidaemia in those most at risk).
Since the SCORE algorithm utilizes total cholesterol levels for calculation of CVD-related
mortality risk, we have assumed that the benefit of LDL-C control was approximately equiva-
lent to the benefit of reducing the level of total cholesterol among the uncontrolled patients to
the mean total cholesterol level in patients with controlled dyslipidaemia. Statistical analyses
were carried out using SAS (V9.2, SAS Institute Inc., Cary, NC, USA).
Results
Patient demographics and general characteristics
Of the 7641 patients in the overall EURIKA population, we defined two groups for analysis:
(i) a high-risk group comprising all participants who had a SCORE of5% and/or who were
already receiving lipid-lowering therapy, and (ii) a very-high-risk group of patients who had
either a SCORE of10% or a diagnosis of diabetes mellitus. For the purposes of this analysis,
we considered the PCP’s decision to treat those patients already receiving lipid-lowering thera-
py as a determination that they were at high-risk. A total of 5019 patients were found to be in
the high-risk group (65.7% of the total EURIKA population), 2970 in the very-high-risk group
(38.9% of the total EURIKA population). Of the high-risk patients, 2465 (49.1%) were also in
the very-high-risk group; only 505 patients with diabetes mellitus in the very-high-risk group
were not also included in the high-risk group.
Demographic information for these two groups is presented in Table 1. Patients in the high-
risk group had a mean age of 66.1 years, there were more men than women (54.6% vs. 45.4%)
and 21.3% were smokers. The prevalence of hypertension was 76.5% and a total of 73.4% had a
prior diagnosis of dyslipidaemia. The prevalence of diabetes mellitus was 30.7%. Patient char-
acteristics were generally similar in the high-risk and very-high-risk groups. The mean age of
very-high-risk patients was 67.2 years, 42.1% were female and 79.9% had hypertension. The
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proportion of patients who had received a prior diagnosis of dyslipidaemia (62.1%) was lower
in the very-high-risk group than in the high-risk group, and the proportion who had diabetes
mellitus (68.9%) was higher. If all patients with diabetes mellitus were excluded from the very-
high-risk group, the mean SCORE-based 10-year risk of CVD-related mortality was 17.3%
(standard deviation: 7.9).
Dyslipidaemia: LDL-C levels4.1 mmol/L (160 mg/dL), or HDL-C levels<1.036 mmol/L
(40 mg/dL) for men or<1.300 mmol/L (50 mg/dL) for women, or TG levels1.7 mmol/L
(150 mg/dL); hypertension: SBP140 mmHg, or DBP90 mmHg.
BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein
cholesterol, LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; SBP,
systolic blood pressure; SCORE, Systematic Coronary Risk Evaluation; TC, total cholesterol;
TG, triglycerides.
Lipid-lowering therapy and control of LDL-C levels
High-risk patients. Among those in the high-risk group, 3278 (65.3%) were receiving lipid-
lowering therapy (Table 2). The majority of these patients (87.3%) were receiving a statin
Table 2. Use of lipid-lowering therapy.
High-risk(SCORE 5%, or
receiving LLT)
Very-high-risk(SCORE 10%, or
diabetes mellitus)
(n = 5019) (n = 2970)
Any LLT 3278 (65.3) 1469 (49.5)
Statins alone 2862 (87.3) 1299 (88.4)
Statins with additional non-
statin LLTa
178 (5.4) 86 (5.9)
Non-statin LLTa 238 (7.3) 84 (5.7)
aNon-statin LLT: ezetimibe, ﬁbrates, nicotinic acid, anion exchange resins.
LLT, lipid-lowering therapy; SCORE, Systematic Coronary Risk Evaluation.
doi:10.1371/journal.pone.0115270.t002
Table 1. Baseline patient characteristics.
High-risk (SCORE 5%, or
receiving LLT)
Very-high-risk(SCORE 10%, or
diabetes mellitus)
(n = 5019) (n = 2970)
Age, years 66.1 (8.9) 67.2 (9.5)
Female, n (%) 2277 (45.4) 1250 (42.1)
Dyslipidaemia, n (%) 3683 (73.4) 1844 (62.1)
TC, mmol/L 5.3 (1.2) 5.2 (1.2)
LDL-C, mmol/L 3.1 (1.0) 3.0 (1.0)
HDL-C, mmol/L 1.4 (0.4) 1.4 (0.4)
TG, mmol/L 1.8 (1.4) 1.9 (1.5)
Hypertension, n (%) 3839 (76.5) 2372 (79.9)
SBP, mmHg 137.1 (17.0) 139.5 (17.8)
DBP, mmHg 80.8 (10.1) 80.9 (10.4)
BMI, kg/m2 28.8 (5.2) 29.6 (5.7)
Current smoker, n (%) 1061 (21.3) 580 (19.7)
Diabetes mellitus, n
(%)
1541 (30.7) 2046 (68.9)
Data are mean (SD) unless otherwise indicated.
doi:10.1371/journal.pone.0115270.t001
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alone. A further 5.4% were receiving a statin in combination with a non-statin lipid-lowering
treatment, and 7.3% were receiving a non-statin lipid-lowering treatment alone. Non-statin
lipid lowering treatments included ezetimibe, fibrates, nicotinic acid and anion exchange res-
ins. Data concerning LDL-C levels were available for 3151 (96.1%) of those in the high-risk
group receiving any form of lipid-lowering therapy, showing that 1931 (61.3%) of these treated
patients still had uncontrolled LDL-C levels (2.5 mmol/L [mean 3.4]) (Fig. 1). A total of 1231
(39.1%) had LDL-C levels3.0 mmol/L.
Very-high-risk patients. In total, 1469 (49.5%) patients who had a SCORE of10% or dia-
betes mellitus were receiving any form of lipid-lowering therapy (Table 2). Among these,
88.4% were receiving a statin alone. A further 5.9% were receiving a statin in combination with
a non-statin lipid-lowering treatment, and 5.7% were receiving a non-statin lipid-lowering
treatment alone. Data concerning LDL-C levels were available for 1401 (95.4%) of the patients
receiving any form of lipid-lowering therapy, of whom 1161 (82.9%) still had uncontrolled
LDL-C levels (1.8 mmol/L [mean 2.9]) (Fig. 1). A total of 694 (49.5%) had LDL-C levels
2.5 mmol/L.
Attributable risk
Among patients in the high-risk group, the excess SCORE-based 10-year risk of CVD-related
mortality attributable to uncontrolled dyslipidaemia (AR) was 0.72% (95% confidence interval
[CI]: 0.67–0.77%), which translates into a %AR of 12.1% (95% CI: 11.7–12.6%). For the very-
high-risk patients, the corresponding figures were 1.61% (95% CI: 1.49–1.72%) and 16.5%
(95% CI: 15.4–16.7%).
Figure 1. Percentage of patients in the high-risk and very-high-risk groups receiving any form of lipid-
lowering therapy (LLT) who have controlled and uncontrolled levels of low-density lipoprotein
cholesterol (LDL-C). Patients for whom data regarding LDL-C levels were not available were excluded.
Controlled LDL-C levels were defined as<2.5 mmol/L in the high-risk group (including patients who are also
included in the very-high-risk group), and<1.8 mmol/L in the very-high-risk group.
doi:10.1371/journal.pone.0115270.g001
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Use of low-intensity and high-intensity statins
The proportions of patients in the high-risk and very-high-risk groups who had controlled or
uncontrolled LDL-C levels and who were receiving either a high-intensity or low-intensity stat-
in are shown in Fig. 2. Among the high-risk patients, of those with uncontrolled LDL-C levels
only 8.7% were receiving a high-intensity statin. Among the very-high-risk group, of those
with uncontrolled LDL-C levels only 8.4% were receiving a high-intensity statin. The propor-
tions of patients receiving high-intensity and low-intensity statins were similar among those
with controlled LDL-C levels and those with uncontrolled LDL-C levels in both the high-risk
and the very-high-risk groups of patients.
Discussion
In this analysis of data from a large, multinational study of the primary prevention of CVD in
Europe, we have demonstrated that there remains considerable potential for improvement in
the treatment of dyslipidaemia. Of the patients in the group defined as being at high-risk of
CVD, over a third (34.7%) were not receiving lipid-lowering therapy, despite their elevated
level of risk and guidelines recommending pharmacological intervention with a statin in such
individuals [12, 13]. A total of 73.4% of patients in this group had received a prior diagnosis of
dyslipidaemia. The situation was even more striking in the very-high-risk group, of whom over
half (50.5%) were not receiving any form of lipid-lowering therapy, despite their considerable
level of risk and a previous diagnosis of dyslipidaemia in almost two thirds (62.1%). Thus, it is
likely that many patients in the general population for whom statin therapy would be of benefit
are not receiving appropriate treatment.
Furthermore, among those who were receiving any form of lipid-lowering therapy, LDL-C
levels were only controlled (according to European guideline recommendations [3]) in 38.7%
Figure 2. Percentage of high-risk (A) and very-high-risk (B) patients with controlled or uncontrolled low-density lipoprotein cholesterol (LDL-C)
levels who are treated with low-intensity statins (LIS) or high-intensity statins (HIS). Controlled LDL-C levels were defined as<2.5 mmol/L in the high-
risk group (including patients who are also included in the very-high-risk group), and<1.8 mmol/L in the very-high-risk group. LIS: pravastatin, simvastatin,
lovastatin, fluvastatin, atorvastatin<40 mg or rosuvastatin<20 mg; HIS: atorvastatin 40 mg or rosuvastatin 20 mg.
doi:10.1371/journal.pone.0115270.g002
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of the patients in the high-risk group, and 17.1% of those in the very-high-risk group. Approxi-
mately 12–16% of the SCORE-based 10-year risk of CVD-related mortality in high-risk and
very-high-risk patients is attributable to suboptimal control of dyslipidaemia. Among those
with uncontrolled LDL-C levels who were receiving lipid-lowering therapy, only 8.7% and
8.4% of the high-risk and very-high-risk patients, respectively, were receiving a high-intensity
statin. Hence, there is considerable potential for optimization of the dose and/or form of statin
treatment for high-risk and very-high-risk patients. A further possible explanation for the lack
of control of LDL-C levels amont patients receiving lipid lowering therapy is non-compliance
to treamtent. Although the data in our study do not allow us to test this hypothesis, it is possi-
ble that strategies to improve patient compliance could be of clinical benefit.
It was notable that the proportion of patients receiving a high-intensity statin was similar
among patients with controlled dyslipidaemia and patients with uncontrolled dyslipidaemia, in
both the high-risk and very-high-risk groups of patients. One potential explanation for this is
that PCPs prescribe high-intensity treatment to patients with higher pretreatment cholesterol
levels, for whom cholesterol level control is likely to be more difficult to achieve. Unfortunately,
the evaluation of pretreatment cholesterol levels was not included in our study, preventing a
formal test of this hypothesis. Evidence suggests that patients with uncontrolled LDL-C levels
receiving a lower intensity treatment are likely to derive additional benefit from more intensive
therapy, if tolerated [3, 12, 13].
We also found that only 5.4% and 5.9% of the high-risk and very-high-risk patients, respec-
tively, were receiving statin therapy in combination with another lipid-lowering agent. There is
potential to improve control of lipid levels by addition of other agents to statin therapy, although
definitive trial evidence showing that this will result in reductions in CVD event rates over the
use of optimal statin doses is currently lacking. The Improved Reduction of Outcomes: Vytorin
Efficacy International Trial (IMPROVE-IT), examining whether a fixed-dose combination of
ezetimibe and simvastatin offers improved cholesterol-lowering efficiency over simvastatin
alone, is still ongoing. Nicotinic acid agents and fibrates may also be considered, although these
agents are used more commonly to address HDL-C and triglyceride abnormalities [20, 21].
Our results are in line with those of previous studies: a study conducted in Italy has shown
that among patients prescribed a statin, only 22.6% were within 10% of their target LDL-C
levels after 12 months of treatment [22]. A literature review published in 2004 has similarly re-
ported a widespread failure to treat patients with dyslipidaemia who should be receiving lipid-
lowering therapy, and failure to reach cholesterol target levels among those who are treated
[23]. This finding remains true in the USA; a recent systematic review of five population-based
studies including data from 18 656 participants found that among patients at high cardiovascu-
lar risk, achievement of an LDL-C target of 100 mg/dL increased from only 24% to 50.4% be-
tween 1999 and 2008 [24]. In the same time period, the proportion of patients with LDL-C
levels 130 mg/dL and not receiving lipid lowering therapy decreased from 29.4% to 18%. Our
study is the first to evaluate these issues systematically across a large group of European patients
with varying levels of CVD risk, who have one or more cardiovascular risk factors but who are
free from CVD. Previously, we have reported from EURIKA the finding that only 41.2% of pa-
tients with dyslipidaemia attained both their total cholesterol and LDL-C target levels [4].
Proper selection of lipid-lowering therapy and effective control of cholesterol levels has
been proven to be of benefit: a meta-analysis by the Cholesterol Treatment Trialists’ collabora-
tors has shown that statin treatment can result in a 23% reduction in cardiovascular events and
a 19% reduction in CVD-related mortality per 1 mmol/L reduction in patients’ LDL-C levels
[25]. The same group has more recently demonstrated that statin treatment is of benefit to pa-
tients across the whole spectrum of CVD risk, even in those at low-risk and intermediate-risk
[26]. It should be noted, however, that the absolute magnitude of risk reduction with statin
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therapy is greater with increasing level of risk. Thus, both the clinical- and cost-effectiveness of
statin therapy increases with patients’ absolute level of cardiovascular risk. Although a recent
retrospective study has shown that patients initiating a high intensity statin have a higher prob-
ability of hospitalization due to acute kidney injury (AKI) in the first 3 months of therapy than
patients initiating a low-intensity statin therapy [27], the absolute risk of AKI is low. Compara-
tive data regarding the impact of therapy on hard cardiovascular outcomes in the study popula-
tion was not reported, and the largest meta-analysis of randomised controlled trials to date has
failed to detect a significant rate of AKI in patients receiving statins [26]. Therefore, although
the exact impact of statin therapy on AKI remains controversial, the potential risk is currently
outweighed by the established cardiovascular benefit of effective therapy in the intermediate-
risk to high-risk patients so far studied.
A strength of our study was the testing of a large sample of patients frommultiple countries
according to standardized procedures. The participation acceptance rate among physicians was
low, but the random selection of patients and a relatively high patient acceptance rate of 62.1%
are likely to have reduced patient selection bias. As the data-collection period for each country
was only 3 months, it is possible that frequent healthcare service users were overrepresented in
the study cohort, which may bias the patient population towards the inclusion of less healthy pa-
tients. In addition, a detailed evaluation of patients’ previous use of statins, including tolerance
or history of adverse effects, was not conducted. These variables may explain lack of use of lipid-
lowering therapy or failure to reach LDL-C targets in some patients. The lack of information re-
garding pretreatment cholesterol levels prevented an evaluation of the proportion of very-high-
risk patients who had achieved a50% reduction in LDL-C, but still had levels1.8 mmol/L.
We conclude that there remains a considerable treatment gap with regard to lipid manage-
ment among patients at high-risk and very-high-risk of CVD in primary care in Europe. This
treatment gap could be closed by more rigorous calculation of global CVD risk in potentially
at-risk patients, with prescription of statins for those at high-risk or very-high-risk, and treat-
ment intensification until guideline-recommended total cholesterol and LDL-C levels are
achieved. Improving lipid management in higher risk patients, primarily by optimizing the use
of statin therapy, could significantly reduce the burden of CVD in Europe.
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